Solid tumor
Conditions
Interventions
The group for observing solid tumors:None
Sponsors
Eastern Theater General Hospital of the Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with a confirmed diagnosis of solid tumor via cytological or histological pathological examination; 2. Patients scheduled to receive at least one cycle of immune checkpoint inhibitor (ICIs) therapy (including monotherapy and combination therapy regimens; ICIs mainly include PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, PD-1+VEGF bispecific antibodies, PD-1+CTLA-4 bispecific antibodies (bispecific antibodies or combined dual antibodies), etc., excluding cell infusion therapies such as DC, CIK, and CAR-T); 3. Patients with normal cognitive function who can understand and complete the patient adverse reaction questionnaires and relevant scales required by the study; 4. Patients who have voluntarily signed this informed consent form.
Exclusion criteria
Exclusion criteria: 1. Severe cardiovascular underlying diseases (Class II or above congestive heart failure, unstable angina pectoris, myocardial infarction, uncontrolled arrhythmias); 2. Previous radiotherapy to the left chest or heart, or heart surgery (including stent, valve, etc. surgeries); 3. Severe mental disorders, as judged by the researchers, that prevent the participant from completing the study; 4. Poor compliance or the researchers' judgment that the participant is unable to complete the study in any circumstances.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence rate of immune-mediated myocarditis;Prognosis; | — |
Countries
China
Contacts
Public ContactXiaoyuan Chu,Feng Wang
Eastern Theater General Hospital of the Chinese People's Liberation Army
Outcome results
None listed